Blueprint Medicines (BPMC) PT Lowered to $128 at Wedbush, Following Earnings
Tweet Send to a Friend
Wedbush analyst David Nierengarten lowered the price target on Blueprint Medicines (NASDAQ: BPMC) to $128.00 (from $139.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
